These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11279803)

  • 1. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
    Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
    Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.
    Crombet T; Torres O; Rodríguez V; Menéndez A; Stevenson A; Ramos M; Torres F; Figueredo R; Veitía I; Iznaga N; Pérez R; Lage A
    Hybridoma; 2001 Apr; 20(2):131-6. PubMed ID: 11394532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
    Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
    J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
    J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
    Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
    J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
    Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
    J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.
    Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA
    Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
    Crombet T; Torres L; Neninger E; Catalá M; Solano ME; Perera A; Torres O; Iznaga N; Torres F; Pérez R; Lage A
    J Immunother; 2003; 26(2):139-48. PubMed ID: 12616105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability.
    Morales AA; Núñez-Gandolff G; Pérez NP; Véliz BC; Caballero-Torres I; Ducongé J; Fernández E; Crespo FZ; Veloso A; Iznaga-Escobar N
    Nucl Med Biol; 1999 Aug; 26(6):717-23. PubMed ID: 10587113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?
    Ducongé J; Fernández-Sánchez E; Alvarez D
    Biopharm Drug Dispos; 2004 May; 25(4):177-86. PubMed ID: 15108220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization.
    Iznaga-Escobar N; Ramos-Suzarte M; Morales-Morales A; Torres-Arocha L; Rodríguez-Mesa N; Pérez-Rodriguez R
    Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):687-96. PubMed ID: 15632954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
    Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
    Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
    Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
    Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
    J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.
    Xiao J; Horst S; Hinkle G; Cao X; Kocak E; Fang J; Young D; Khazaeli M; Agnese D; Sun D; Martin E
    Cancer Biother Radiopharm; 2005 Feb; 20(1):16-26. PubMed ID: 15778575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.